Narrative Update • Aug 17
Have your own idea? Try our Stock Screener
Chinese (SSE) Life Sciences Industry Analysis
UpdatedAug 27, 2026
DataAggregated Company Financials
Companies27
- 7D-2.6%
- 3M46.9%
- 1Y39.6%
- YTD41.5%
Over the last 7 days, the Life Sciences industry has dropped 4.4%, driven by a pullback from WuXi AppTec of 3.0%. In contrast, MGI Tech has gained 16%. This takes the industry's 12 month performance to a gain of 39%. As for the next few years, earnings are expected to grow by 22% per annum.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 27 Aug 2026 | CN¥815.5b | CN¥105.3b | CN¥23.5b | 72.9x | 34.8x | 7.7x |
| Sat, 25 Jul 2026 | CN¥660.8b | CN¥98.8b | CN¥21.9b | 63.1x | 30.2x | 6.7x |
| Mon, 22 Jun 2026 | CN¥552.3b | CN¥98.8b | CN¥21.9b | 52.8x | 25.3x | 5.6x |
| Wed, 20 May 2026 | CN¥577.6b | CN¥98.7b | CN¥21.7b | 56.9x | 26.6x | 5.9x |
| Fri, 17 Apr 2026 | CN¥616.4b | CN¥95.0b | CN¥20.7b | 65.2x | 29.7x | 6.5x |
| Sun, 15 Mar 2026 | CN¥547.6b | CN¥94.5b | CN¥18.7b | 61x | 29.4x | 5.8x |
| Tue, 10 Feb 2026 | CN¥606.1b | CN¥94.4b | CN¥18.6b | 64.5x | 32.7x | 6.4x |
| Thu, 08 Jan 2026 | CN¥600.4b | CN¥94.3b | CN¥18.5b | 62.4x | 32.4x | 6.4x |
| Sat, 06 Dec 2025 | CN¥541.5b | CN¥94.3b | CN¥18.5b | 63.3x | 29.2x | 5.7x |
| Mon, 03 Nov 2025 | CN¥601.9b | CN¥93.5b | CN¥18.8b | 66.3x | 32x | 6.4x |
| Wed, 01 Oct 2025 | CN¥637.6b | CN¥92.1b | CN¥17.4b | 70.8x | 36.6x | 6.9x |
| Fri, 29 Aug 2025 | CN¥578.3b | CN¥92.5b | CN¥17.6b | 58x | 32.8x | 6.3x |
| Sun, 27 Jul 2025 | CN¥546.8b | CN¥89.8b | CN¥15.4b | 58x | 35.6x | 6.1x |
| Tue, 24 Jun 2025 | CN¥418.7b | CN¥89.8b | CN¥15.4b | 46.1x | 27.2x | 4.7x |
| Thu, 22 May 2025 | CN¥398.9b | CN¥89.1b | CN¥15.3b | 44.3x | 26.1x | 4.5x |
| Sat, 19 Apr 2025 | CN¥364.3b | CN¥88.6b | CN¥14.0b | 36x | 26x | 4.1x |
| Mon, 17 Mar 2025 | CN¥441.1b | CN¥89.0b | CN¥11.3b | 43.4x | 38.9x | 5x |
| Wed, 12 Feb 2025 | CN¥392.0b | CN¥88.1b | CN¥11.2b | 40.1x | 34.9x | 4.4x |
| Fri, 10 Jan 2025 | CN¥346.9b | CN¥88.1b | CN¥11.2b | 32.8x | 30.9x | 3.9x |
| Sun, 08 Dec 2024 | CN¥393.4b | CN¥87.8b | CN¥11.2b | 41.5x | 35.2x | 4.5x |
| Tue, 05 Nov 2024 | CN¥373.0b | CN¥87.8b | CN¥11.2b | 37.6x | 33.3x | 4.2x |
| Thu, 03 Oct 2024 | CN¥379.0b | CN¥88.2b | CN¥12.4b | 35.3x | 30.6x | 4.3x |
| Sat, 31 Aug 2024 | CN¥277.7b | CN¥87.1b | CN¥12.1b | 28.1x | 23x | 3.2x |
| Mon, 29 Jul 2024 | CN¥278.6b | CN¥88.3b | CN¥13.4b | 25.9x | 20.8x | 3.2x |
| Wed, 26 Jun 2024 | CN¥285.5b | CN¥88.3b | CN¥13.4b | 24.4x | 21.3x | 3.2x |
| Fri, 24 May 2024 | CN¥318.5b | CN¥88.3b | CN¥13.3b | 28.2x | 23.9x | 3.6x |
| Sun, 21 Apr 2024 | CN¥303.1b | CN¥90.4b | CN¥15.0b | 29.9x | 20.2x | 3.4x |
| Tue, 19 Mar 2024 | CN¥378.3b | CN¥90.5b | CN¥15.5b | 35.2x | 24.4x | 4.2x |
| Thu, 15 Feb 2024 | CN¥348.7b | CN¥91.1b | CN¥16.1b | 29.9x | 21.7x | 3.8x |
| Sat, 13 Jan 2024 | CN¥456.5b | CN¥91.1b | CN¥16.1b | 35.3x | 28.4x | 5x |
| Mon, 11 Dec 2023 | CN¥493.2b | CN¥91.1b | CN¥16.1b | 36.4x | 30.7x | 5.4x |
| Wed, 08 Nov 2023 | CN¥562.5b | CN¥91.0b | CN¥16.1b | 40.6x | 35x | 6.2x |
| Fri, 06 Oct 2023 | CN¥519.9b | CN¥92.0b | CN¥18.3b | 35.6x | 28.3x | 5.7x |
| Sun, 03 Sep 2023 | CN¥494.7b | CN¥91.8b | CN¥18.3b | 34.7x | 27.1x | 5.4x |
Price to Earnings Ratio
27.1x
Current Industry PE
- Investors are optimistic on the Chinese Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 35.5x which is higher than its 3-year average PE of 29.0x.
- The 3-year average PS ratio of 5.1x is lower than the industry's current PS ratio of 7.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 8.6% per year over the last three years.
- Revenues for these companies have grown 4.6% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 0.044% | |
| Healthcare | -1.09% | |
| Life Sciences | -2.61% | |
| Clinical Research and Equipment | -2.61% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688114 MGI Tech | CN¥66.54 | 15.5% +CN¥3.7b | -8.2% | PS9.1x | |
| 688202 Shanghai Medicilon | CN¥104.23 | 4.4% +CN¥574.9m | 67.4% | PS9.9x | |
| 688710 Shanghai InnoStar Bio-tech | CN¥93.97 | 3.2% +CN¥408.8m | 139.7% | PE555.5x | |
| 688315 Novogene | CN¥15.82 | 6.4% +CN¥384.8m | -0.2% | PE42.3x | |
| 688238 Shanghai Obio Technology (Group) | CN¥7.14 | 5.8% +CN¥245.8m | -10.5% | PS16.7x |